Related Experiment Video

Updated: Jun 8, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Adjunctive pharmacologic therapy in percutaneous coronary intervention: part I antiplatelet therapy

Soo-Joong Kim1, Robert P Giugliano, Ik-Kyung Jang

  • 1Department of Cardiology, College of Medicine, Kyung Hee University, Seoul, Korea.

Coronary Artery Disease
|October 8, 2010
PubMed

Insights

Percutaneous coronary intervention (PCI) reduces thrombotic complications in ischemic heart disease. Antiplatelet therapies like aspirin, clopidogrel, and glycoprotein IIb/IIIa inhibitors are crucial for improving PCI outcomes.

Area of Science:

  • Cardiology
  • Vascular Medicine
  • Pharmacology

Background:

  • Ischemic heart disease is a leading global cause of death.
  • Percutaneous coronary intervention (PCI) is a key treatment for coronary heart disease.
  • PCI procedures can trigger thrombotic complications due to plaque disruption and endothelial injury.

Purpose of the Study:

  • To review the role of pharmacological adjuvant therapies in managing PCI-related thrombotic complications.
  • To highlight the evolution and efficacy of antiplatelet and antithrombin agents in PCI.

Main Methods:

  • Review of current literature on antiplatelet and antithrombin therapies used during PCI.
  • Analysis of the impact of various drugs on reducing thrombosis after stent placement.
  • Discussion of emerging pharmacological agents for PCI.

Main Results:

  • Aspirin is a foundational therapy for ischemic heart disease.
  • Clopidogrel and prasugrel significantly reduce stent thrombosis rates.
  • Glycoprotein IIb/IIIa inhibitors enhance PCI outcomes, particularly in high-risk individuals.

Conclusions:

  • Pharmacological therapies are indispensable for preventing thrombotic complications during PCI.
  • The development of new antiplatelet and antithrombin drugs continues to advance PCI treatment.
  • Optimizing adjuvant therapy improves patient outcomes in ischemic heart disease management.

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...